Should We Enter a New Market?
in HealthTech & Digital Health

The short answer

Market size and PMPM are the easy half. The ability to carry outcomes risk inside the measurement window is the half that decides the outcome. For digital health companies, this shows up in a particular place. The numbers that carry the answer are at-risk revenue share and engagement rate, and the complication specific to this industry is that outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle. The general version of this problem and the one you are actually in have different first moves.

New markets get evaluated on enrolled members and ARR growth, both of which are knowable and neither of which predicts success. The predictive question is what you already have that transfers — an engagement mechanism that produces attributed outcomes, a contract structure that aligns at-risk share with gross margin, or data that shortens the time to demonstrated results — and what must be built from zero while an 11-month sales cycle runs against a 12-month measurement window.

A market can show strong PMPM and still be a bad bet if the operator cannot sustain the engagement rate required to support the at-risk revenue share it has already signed. The reverse holds as well: a slower-growing segment where existing contracts already produce stable logo churn and margin will usually outperform one that demands new risk terms the operator has not yet proven it can meet.

The other discipline is a stated kill criterion before entry, because at-risk arrangements are unusually good at consuming budget quietly for years on the argument that engagement or attributed outcomes are nearly where they need to be.

How to tell this is actually your problem

These three together are the signature. One on its own usually points somewhere else.

✓ The case presented to the CEO or CFO rests mainly on projected member growth and PMPM without a model that ties those figures to the engagement rate needed to carry the at-risk share.
✓ No one has written down the engagement rate or logo churn threshold that would trigger exit from the new contract structure.
✓ Core ARR is flat and the new market is being asked to offset the gap while the existing book of at-risk contracts continues to expand.

The move that usually makes it worse. Entering because core ARR has stalled, which pulls management attention away from fixing the engagement and margin problems that already exist in the signed contracts.

Who this is for — and who it is not

It is for you if you run or finance a digital health company and the case rests mainly on market size and growth rate. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.

It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.

Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.

What this looks like when the analysis is actually run

Below is an excerpt from a real run of this analysis on a digital health company. It is a sample profile rather than a customer, and it is unedited engine output — this is the format you get, on your own numbers.

The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.

This is one move out of a full analysis. Read a complete report — every page, no email required.

What the engine does with this question

This question routes to Market Entry & Expansion Strategy, one of 29 engagements the platform runs. For digital health companies it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.

You watch the analysis get built before paying anything. Read a complete report here if you would rather see the depth first.

Questions people ask about this

How do I judge right to win?

List what you already own that the new market values, and what a credible incumbent there owns that you do not. If the second list is longer and includes anything structural — distribution, regulation, data depth — entry is a build, not an extension.

How long should a market entry take to pay back?

Set the number before you start, and treat exceeding it as the kill criterion rather than as a reason to invest more. Most failed entries were never killed, only slowly starved.

Is it better to expand geographically or into a new segment?

Whichever reuses more of what you already have. Geography usually reuses the product and rebuilds distribution; a new segment usually reuses distribution and rebuilds the product. Whichever rebuild is smaller is the safer bet.

Is this different in healthtech & digital health than in other industries?

Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.

What data do I need before this analysis is worth running for a digital health company?

Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.

When is Percision the wrong tool?

Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.

Does Percision replace a lawyer, tax advisor, auditor, or AI implementation team?

Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.